BeyondSpring Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform. The company's lead asset is Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia (CIN). It also develops Plinabulin in combination with Plinabulin+docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy and radiation; nivolumab, a PD-1 antibody that has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer (ES-SCLC); in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small-molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
FLORHAM PARK, N.J., May 18, 2026 -- BeyondSpring Inc. , a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced an upcoming...
Shares of BeyondSpring (NASDAQ:BYSI) climbed more than 6% in premarket trading on Wednesday after the company reported a smaller loss from continuing operations and highlighted progress across its development pipeline. The stock gained 6.
Gainers Quantum Cyber (NASDAQ:QUCY) shares increased by 55.0% to $0.5 during Wednesday's pre-market session. The market value of their outstanding shares is at $4.0 million. SELLAS Life Sciences Gr (NASDAQ:SLS) shares increased by 21.26% to $6.33. The market value of their outstanding shares is at $963.2 million. The company's, Q1 earnings came out yesterday. Whitehawk Therapeutics (NASDAQ:WHWK) stock rose 20.17% to $4.71. The market value of their outstanding shares is at $193.8 million. As per
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.05) per share. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year.
AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate -Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First...
New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC Drugs — With or Without Immunotherapy Plinabulin’s...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
BeyondSpring (NASDAQ:BYSI) reported quarterly losses of $(0.05) per share.
FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in the Immuno-Oncology 360° (IO360°) Conference 2026, held February 10-12, 2026 in Boston, MA. Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1/PD-LD
Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC. FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced results from the Asian subset (n=488) of its global Phase 3 DUBLIN-
Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT
In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC patients. Supported by anti-cancer efficacy and safety in significant reduction exposure-adjusted grade 3/4 adverse events in DUBLIN-3, BeyondSpring will conduct DUBLIN-4, a global, double-blind Phase 3
In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 231.1K | $379.04K | 0.00% | Unchanged | 2026-03-31 |
| RenTech | quant | 11.1K | $18.20K | 0.00% | Added+0.9% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-12upcoming | — | — | — |
| 2022-04-14 | -0.22 | -0.24 | -10.77% |
| 2021-12-30 | -0.30 | -0.47 | -58.43% |
| 2021-09-10 | -0.29 | -0.49 | -70.43% |
| 2021-06-16 | -0.57 | -0.44 | +22.81% |
| 2021-04-30 | -0.43 | -0.52 | -20.00% |
| 2020-11-17 | -0.52 | -0.48 | +7.69% |
| 2020-09-02 | -0.59 | -0.46 | +22.03% |
| 2020-06-11 | -0.46 | -0.58 | -24.73% |
| 2020-04-30 | -0.52 | -0.52 | — |
| 2019-12-18 | -0.30 | -0.37 | -23.33% |
| 2019-12-17 | -0.55 | -0.39 | +29.09% |
| 2019-09-18 | -0.53 | -0.32 | +39.62% |
| 2019-07-10 | -0.63 | -0.32 | +49.21% |
| 2019-04-30 | -0.55 | -0.64 | -16.36% |
| 2018-10-23 | -0.70 | -0.54 | +22.86% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BYSI | +12.75% | +8.39% | +3.07% | -3.72% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +9.78% | +13.03% | +6.51% | -16.41% |